Search
for
Sort by
Research 30 of 343
- Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
- Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report
- 0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review
- Women with PCOS have a heightened risk of cardiometabolic and cardiovascular diseases: statement from the Experts Group on Inositol in Basic and Clinical Research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologists (ANMCO)
- Impact of Reducing Obesity in PCOS: Methods and Treatment Outcomes
- EFLÚVIO TELÓGENO ASSOCIADO AO USO DE MEDICAMENTOS EMAGRECEDORES: MECANISMOS FISIOPATOLÓGICOS E EVIDÊNCIAS CLÍNICAS
- CURRENT THERAPEUTIC APPROACHES IN THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME
- current possible treatment approaches of Polycystic Ovary Syndrome (PCOS)
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Current aspects of polycystic ovary syndrome II: treatment of hyperandrogenism, insulin resistance and infertility
- GLP‐1 agonists and hair loss: a call for further investigation
- GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions
- Balancing metabolic optimization and reproductive safety in Polycystic Ovary Syndrome: a Bayesian-informed framework for GLP-1 receptor agonists
- Antidiabetic Management Strategies for Treatment of Polycystic Ovarian Syndrome
- Metabolic syndrome – a new definition and management guidelines A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons
- Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
- The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
- Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
- GLP-1 e Estética: Ozempic Face, Flacidez e Recuperação
- Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
- Dermatological, Trichological and Quality of Life Consequences of GLP ‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey
- The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
- “From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of GLP‐1 receptor agonists in obesity management services
- Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
- Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
- Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends